Ally Bridge Group, a global healthcare investment management firm, led the $50m Series G round in Relievant Medsystems, a commercial-stage medical device company transforming the diagnosis and treatment of vertebrogenic pain, with participation from Endeavour Vision, Vensana Capital, Lightstone Ventures, New Enterprise Associates, Canaan Partners and Morgenthaler Ventures. “This substantial additional funding allows us to further accelerate our efforts to transform the diagnosis and treatment of vertebrogenic pain. We are thrilled to see strong support from Ally Bridge Group and existing investors in this oversubscribed round as we expand Intracept adoption and make this treatment available to more patients and physicians,” Tyler Binney, Relievant Medsystems President and CEO.